Merck Reports Long-Term HPV Vaccine Efficacy Data Spanning Up to 18 Years
核心洞察
Merck (搜索) will present new clinical data at EUROGIN 2026 showing GARDASIL 9 maintains effectiveness for at least 14 years and GARDASIL for up to 18 years following three-dose vaccination.
The studies evaluated long-term vaccine effectiveness in women aged 16-26 years against HPV (搜索) 16/18-related high-grade cervical disease across multiple countries.
Additional data will cover HPV (搜索)-related oropharyngeal cancers and Recurrent Respiratory Papillomatosis (搜索), reinforcing vaccination importance for both males and females.
Merck (搜索) will present compelling long-term efficacy data for its HPV (搜索) vaccines at the EUROGIN International Multidisciplinary HPV Congress 2026 in Vienna, Austria, demonstrating sustained protection against HPV-related cancers and diseases for up to 18 years following vaccination.
The pharmaceutical company announced it will share new clinical and real-world data showing vaccine effectiveness for at least 14 years following three doses of GARDASIL 9 (9-valent HPV (搜索) vaccine) and up to 18 years after three doses of GARDASIL (4-valent HPV vaccine) against HPV 16/18-related high-grade cervical disease in women aged 16 to 26 years.
Extended Protection Against Multiple HPV-Related Conditions
The data presentation, scheduled for March 18-21, will include studies conducted across the United States, Denmark, Sweden, and the United Kingdom. Beyond cervical disease prevention, Merck (搜索) will present additional findings on HPV (搜索)-related oropharyngeal cancers and both adult- and juvenile-onset Recurrent Respiratory Papillomatosis (搜索) (RRP).
"Nearly two decades after the U.S. FDA approval of GARDASIL in June 2006, we are proud to present these data for GARDASIL 9 and GARDASIL that reinforce the long-term effectiveness and importance of HPV (搜索) vaccination for females ages 9 to 45 years, beginning in adolescence," said Dr. Paula Annunziato, senior vice president of infectious diseases and vaccines, global clinical development at Merck (搜索) Research Laboratories.
Comprehensive Cancer Prevention Coverage
GARDASIL 9 is indicated for prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV (搜索) Types 16, 18, 31, 33, 45, 52, and 58, along with precancerous lesions caused by these and additional HPV types including 6 and 11. The vaccine is approved for females aged 9 through 45 years and males aged 9 through 45 years.
The original GARDASIL vaccine targets HPV (搜索) Types 16 and 18 for cancer prevention and Types 6, 11, 16, and 18 for precancerous lesions, with approval for females aged 9 through 26 years and males aged 9 through 26 years. Both vaccines also prevent genital warts (搜索) caused by HPV Types 6 and 11.
Importance for Both Sexes
Dr. Annunziato emphasized the broader implications of the oropharyngeal cancer (搜索) data, noting that these findings "highlight the importance of HPV (搜索) vaccination in helping to prevent these cancers, which impact both women and men."
The GARDASIL 9 indication for oropharyngeal and head and neck cancers operates under accelerated approval based on effectiveness in preventing HPV (搜索)-related anogenital disease, with continued approval potentially contingent upon verification of clinical benefit in confirmatory trials.
Dosing and Administration
For individuals aged 9 through 14 years, GARDASIL 9 can be administered using either a 2-dose schedule (with the second dose 6-12 months after the first) or a 3-dose schedule at 0, 2, and 6 months. For those aged 15 through 45 years, a 3-dose schedule is required. GARDASIL follows a 3-dose schedule for all individuals aged 9 through 26 years.
The vaccines are administered intramuscularly in the deltoid or anterolateral area of the thigh, with observation for 15 minutes post-administration recommended due to potential syncope reactions.
Both vaccines carry contraindications for individuals with hypersensitivity to yeast or previous vaccine doses, and their safety and effectiveness have not been established in pregnant women. The most common adverse reactions include injection-site pain, swelling, erythema, and headache.